Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial.

At Week 17, SCIT+dupilumab led to nominally significant reductions in sIgE, characterized by median percent change ( Table 4 and Figure 3D ) and median absolute change ( Table 4 ) compared with SCIT.

also in 7,732 other papers

Peak Nasal Inspiratory Flow, Total Ocular Symptom Score, Early-Phase Reaction, and Late-Phase Reaction SCIT+dupilumab showed a trend towards a larger increase (improvement) in mean percent change from baseline in PNIF AUC (0–1 h) compared with SCIT at Week 17 ( Figure 3A ), indicating better nasal patency.

also in 53,322 other papers